Stocktoria
SINOVAC BIOTECH LTD SVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2009-11-13
SINOVAC BIOTECH LTD statistics & valuation
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 67.9% | 61.1% | 68.8% | 55.3% | 94.9% |
| Operating margin | -127.0% | -139.9% | -151.9% | -34.5% | 91.0% |
| Net margin | — | — | -2.9% | 1.0% | 41.9% |
| FCF margin | -145.4% | -42.3% | -3.7% | -75.5% | 76.1% |
| Return on assets | — | — | -0.1% | 0.1% | 48.5% |
| Return on equity | — | — | -0.1% | 0.1% | 59.9% |
| Debt / equity | 0.08× | 0.04× | 0.02× | 0.00× | 0.00× |
| Current ratio | 4.59 | 7.33 | 8.97 | 9.00 | 5.93 |
| Revenue growth | 6.8% | -23.1% | -68.1% | -92.4% | 3692.5% |
Source: SEC EDGAR filings · CIK 0001084201 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.